
Comprehensive Genomic Profiling
Latest Content

Latest Videos

More News

A provisional clinical opinion from the American Society of Clinical Oncology (ASCO) recommends that patients with advanced cancer with specific genomic alterations undergo genomic sequencing.

FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.

Genome sequencing of tumors from children and adolescents with recurrent or refractory cancer led to over 100 patients receiving targeted therapies.

Thermo Fisher Scientific will begin accepting submissions for grant proposals focusing on molecular profiling in cancer spaces, where applicants could receive up to $200,000 in funding.

A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.

Foundation Medicine’s circulating tumor DNA (ctDNA) detection and monitoring assay, FoundationOne Tracker, was granted a Breakthrough Device Designation from the FDA, streamlining the approval and review processes to give patients and providers earlier access to the device.

Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.

The rise in popularity of genetic testing brings along a myriad of challenges ranging from concerns on data privacy to insurance coverage, but, when utilized correctly, it could mark a step forward for significant advancements in individual and population health.

Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.

Findings presented at the 2022 ASCO Gastrointestinal Cancers Symposium showed no significant differences in tissue and plasma genomic profiles of patients with early-onset and late-onset colorectal cancer, but a greater enrichment of the BRCA1 and PTEN mutations were noted in the tissue of those with early-onset disease.

The frequency of several mutations that inhibit response to tyrosine kinase inhibitors and tend to lead to increased disease severity was elevated in Chinese patients with non-small cell lung cancer.

Prior to receiving therapy for non–small cell lung cancer (NSCLC), some patients' results may require analysis beyond comprehensive genomic profiling (CGP).

An increase in the use of comprehensive genomic profiling among patients with advanced non–small cell lung cancer (NSCLC) was associated with additional life-years gained and a low-cost budget impact.

Posters from the Academy of Managed Care Pharmacy Nexus 2021 meeting detailed how coverage of genetic testing aligns with current guidelines as well as the potential budget impact of expanding access to comprehensive genomic profiling (CGP).

Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.

Megan Olsen, MPH, principal at Avalere, discusses the role that value assessments are expected to play in the future pricing of gene and cell therapies.

The top 5 most-read comprehensive genomic profiling articles of 2021 on AJMC.com largely focused on the use of liquid biopsy and how biomarkers can offer providers new ways to help predict treatment-related outcomes and identify therapeutic targets.

During the discussion of disparities in cancer care, one panelist explained that the National Institutes of Health definition of precision medicine is broader than most people realize.

Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.

Next-generation sequencing (NGS) may be a helpful tool for establishing how B cells migrate and maturate across the blood-brain barrier in multiple sclerosis (MS), potentially providing better insight into the pathophysiologic mechanisms involved in neuro-inflammation.

Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).








